Aberrant methylation of CDKN2A, RASSF1A and WIF1 in sporadic adenocarcinomatous colorectal cancer: Associations with clinicopathological features

Exploring Potential Epigenetic Biomarkers for Colorectal Cancer Metastasis

“…For instance, an analysis of sporadic adenocarcinomatous CRC tissues from both the colon and rectum revealed a higher prevalence of CDKN2A methylation in stage II patients (p-value = 0.012) and those without lymph node metastasis (p-value = 0.011). Furthermore, this study also revealed that CDKN2A methylation was less frequent in stage III (p-value = 0.016) [59]. The discordant results in the literature describing the relationship between CDKN2A gene methylation and lymph node metastasis indicate that other variables such as sample variability, tumour heterogeneity, methodological differences in analysis, potential environmental influences, and variations in statistical approaches may need consideration and further analyses are required.…”

“…The identification of DNA methylation biomarkers involves the use of various methodologies, and their choice depends on whether global or regional methylation analysis is performed [54]. This includes a methylation-specific PCR (MSP), quantitative methylation-specific PCR (Q-MSP), microarray analysis, pyrosequencing, and reduced representation bisulfite sequencing (RRBS) [42,[55][56][57][58][59][60][61][62]. MSP is a PCR-based technique that amplifies specific DNA regions after bisulfite conversion, identifying the methylation status at precise loci using primers targeting methylated or unmethylated sequences [63].…”